Format

Send to

Choose Destination
Retina. 2016 Dec;36(12):2339-2347.

OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF CHOROIDAL NEOVASCULARIZATION IN FOUR INHERITED RETINAL DYSTROPHIES.

Author information

1
Casey Eye Institute, Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon.

Abstract

PURPOSE:

To demonstrate the clinical utility of optical coherence tomography (OCT) angiography (OCT-A) in inherited retinal dystrophies complicated by choroidal neovascularization (CNV).

METHODS:

Optical coherence tomography angiography and structural OCT were performed using a 70-kHz spectral domain OCT system using the split-spectrum amplitude-decorrelation angiography algorithm. Semiautomated image processing software was used to segment and measure the CNV.

RESULTS:

Four participants were enrolled to study the following inherited retinal dystrophies complicated by CNV: choroideremia, EFEMP1-related retinopathy, Best vitelliform dystrophy, and adult-onset vitelliform dystrophy. Interpretation of fluorescein angiography was difficult because of abnormal retinal architecture but suggested the presence of CNV. Structural OCT revealed subretinal or subretinal pigment epithelium fibrovascular tissue, within which flow signal was observed on OCT-A. The CNV morphology varied from dense capillary networks in active lesions to asymptomatic large caliber loops. Baseline CNV vessel areas ranged from 0.07 mm to 0.98 mm. After treatment with intravitreal bevacizumab, the CNV in choroideremia decreased in the vessel area then rebounded, whereas the one in EFEMP1-related retinopathy remained largely unchanged.

CONCLUSION:

Optical coherence tomography angiography enables morphologic characterization and quantification of CNV in patients with retinal dystrophies despite distorted retinal architecture, can assess response to treatment, and may facilitate differentiation between active and regressed lesions.

PMID:
27336230
PMCID:
PMC5115925
DOI:
10.1097/IAE.0000000000001159
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Proprietary interest: Oregon Health & Science University, Y.J., and D.H. have a significant financial interest in Optovue, Inc, a company that may have a commercial interest in the results of this research. These potential conflicts of interest have been reviewed and managed by OHSU. D.H. receives royalties on an optical coherence tomography patent licensed by the Massachusetts Institute of Technology to Carl Zeiss Meditec. R.G.W. serves on Scientific Advisory Boards for the Foundation Fighting Blindness. This relationship has been reviewed and managed by OHSU. The other authors have no proprietary or commercial interest in any materials discussed in this article.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center